Lenalidomide therapy in systemic mastocytosis

Leukemia Research

Volumn 33, Issue 3, 2009, Pages

  Kluin Nelemans, Hanneke C ^a   Ferenc, Veronika ^b   van Doormaal, Jaap J ^a   van Iperen, Charlotte ^c   Peters, Willem G ^d   Akin, Cem ^e   Valent, Peter ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Beatrix Hospital   (Netherlands)

^d CATHARINA HOSPITAL   (Netherlands)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CD2 ANTIGEN; CORTICOSTEROID; IMMUNOGLOBULIN A; INTERLEUKIN 2 RECEPTOR ALPHA; LENALIDOMIDE; M PROTEIN; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ANEMIA; ANOREXIA; BLOOD TRANSFUSION; BONE LESION; BONE MARROW BIOPSY; CANCER CELL; CASE REPORT; CELL INFILTRATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LETTER; MALE; MAST CELL; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OSTEOPOROSIS; PLASMA CELL; PRIORITY JOURNAL; PROPHYLAXIS; SIDE EFFECT; SKELETON RADIOGRAPHY; SYSTEMIC MASTOCYTOSIS; THROMBOCYTE COUNT;

AGED; FEMALE; HUMANS; MALE; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE; TREATMENT OUTCOME;

EID: 58749102979     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.06.013     Document Type: Letter

References (8)

1. Valent P., Horny H.-P., Li C.-Y., et al. Mastocytosis (Mast cell disease). In: Jaffe E.S., Harris N.L., Stein H., et al. (Eds). WHO Classification of tumours: tumours of haematopoietic and lymphoid tissues (2001), IARC Press, Lyon 292-302
2. Valent P., Akin C., Sperr W.R., et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 122 (2003) 695-717
3. Qu Z., Huang X., Ahmadi P., et al. Synthesis of basic fibroblast growth factor by murine mast cells. Regulation by transforming growth factor beta, tumor necrosis factor alpha, and stem cell factor. Int Arch Allergy Immunol 115 (1998) 47-54
4. Sillaber C., Bevec D., Butterfield J.H., et al. Tumor necrosis factor alpha and interleukin-1 beta mRNA expression in HMC-1 cells: differential regulation of gene product expression by recombinant interleukin-4. Exp Hematol 21 (1993) 1271-1275
5. Brockow K., Akin C., Huber M., et al. Levels of mast cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: correlation with dermal mast cell numbers and mast cell tryptase. J Allergy Clin Immunol 109 (2002) 82-88
6. Akin C., Longley J., Brockow K., et al. Effects of the tyrosine-kinase inhibitor STI571 on mutated KIT and neoplastic mast cells. Blood 96 (2000) 747a
7. Sillaber C., Strobl H., Bevec D., et al. IL-4 regulates c-KIT proto-oncogene product expression in human mast and myeloid progenitor cells. J Immunol 147 (1991) 4224-4228
8. List A., Dewald G., Bennett J., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355 (2006) 1456-1465